SUMMARY Fifty-one men with atherosclerotic intermittent claudication and haemorheological abnormalities completed a double-blind, one-year randomised trial of Ticlopidine (500 mg/day), a new antiplatelet agent. Ticlopidine caused significant inhibition of platelet aggregation but did not fully correct abnormalities of coagulation, viscosity, and fibrinolysis. There was no significant improvement in walking ability, Doppler ankle-pressure indices, or calf blood flow. Sustained platelet inhibition for 12 months was insufficient to correct the prothrombotic abnormality of extensive atherosclerosis. The threshold concentrations of adenosine diphosphate (ADP) and collagen required to produce a biphasic aggregation curve and maximal platelet aggregation respectively, were determined8 and,8-thromboglobulin was assayed, on blood taken into EDTA-theophylline, using the kit provided by Amersham International Ltd. Thrombinclottable fibrinogen, factor VIII antigen activity (FVIII R:Ag), and euglobulin lysis time were estimated as previously described.' 8 Plasma viscosity at 25°C was measured using a Coulter-Harkness (Coulter Electronics, Luton) viscometer and whole-blood viscosity at 25°C and shear rates of 128/s and 0-2/s was measured using a Contraves (Zurich) LS 30 viscometer with correction of viscosity to a standard haematocrit of 0-45 1.' 740
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There is widespread interest in the use of antiplatelet agents to prevent thrombotic complications in patients with established vascular disease. Such patients, however, may have extensive atherosclerosis with associated platelet hyperactivity, hyperviscosity, an increase in coagulant proteins, and reduced fibrinolysis.l It is unknown, moreover, whether an antiplatelet agent can be clinically effective in the presence of these multiple abnormalities of a prothrombotic nature. We have investigated this by serial study of haemostatic, haemorheological, and clinical performance tests in patients with atherosclerotic intermittent claudication randomised to take Ticlopidine or placebo for one year.
This new antiplatelet agent (5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno (3,2-C) 
Discussion
The rationale for antiplatelet therapy as prophylaxis against recurrence of myocardial infarction, transient cerebral ischaemic attacks, or other clinical presentations of degenerative vascular disease, is that the platelet role is a predominant one. Even if platelet hyperactivity cannot be demonstrated in an individual patient, it is argued, drug-induced hypoactivity may be beneficial. This hypothesis is less secure if other haemostatic and haemorheological abnormalities of a prothrombotic nature coexist and remain unaltered by platelet inhibition. Platelet hyperactivity,'0-13 hyperfibrinogenaemia and hypervisCosity,8 14 and reduced fibrinolytic activity '5-'7 have all been described in atherosclerosis, including a study of 37 of the 65 patients entered into the present trial.' Moreover, it is uncertain whether these prothrombotic abnormalities are of aetiological significance'8 or collectively represent a nonspecific stress response to established vascular disease.
I
Effective long-term inhibition of platelet deposition on damaged endothelium might simultaneously reduce fibrin deposition so that liver synthesis of coagulant proteins could be reset at a lower level. Since fibrinogen is a major determinant of both plasma viscosity and whole-blood viscosity'920 this might be of rheological as well as haemostatic benefit. Inhibition ot platelet aggregation in severe atherosclerosis might also increase distal limb perfusion so that a larger area of undamaged endothelium would be available to release fibrinolytic activator. Although Ticlopidine caused sustained inhibition of platelet aggregation and a significant fall in fibrinogen concentration, it did not significantly lower plasma-or blood-viscosity, did not reduce the activity of factor VIII R:Ag, and was not associated with increased endothelial cell production of plasminogen activator to a greater extent than placebo. Thus the prothrombotic tendency of our atherosclerotic patients was not fully corrected. In addition, there was no subjective or objective evidence of clinical benefit although the number of patients studied was small. Two recent reports2' 22 suggested that, because of a tendency to spontaneous improvement in younger claudicants, the benefit of drug therapy may be evident only in patients over 60 yr when the disease is relatively static, but no selective clinical benefit was found in our oldest patients. Analysis of the data for all patients at six months showed a statistically significant improvement in peak calf blood flow,23 particularly in those under 60 yr, but the difference was no longer significant at 12 months.
Although Ticlopidine, given for 12 months, did not fully correct the prothrombotic abnormality of patients with extensive atherosclerosis, this result should not be extrapolated to other antithrombotic agents or to patients with less extensive vascular disease. A significant reduction in plasma fibrinogen, which is a major determinant of blood viscosity, is an interesting aspect of Ticlopidine's action which was also noted after four and 12 months' treatment 
